PMID- 18543309 OWN - NLM STAT- MEDLINE DCOM- 20080908 LR - 20151119 IS - 0008-543X (Print) IS - 0008-543X (Linking) VI - 113 IP - 4 DP - 2008 Aug 15 TI - No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia. PG - 772-81 LID - 10.1002/cncr.23607 [doi] AB - BACKGROUND: Although deletion of the derivative chromosome 9 (der 9; del-der 9) carries a poor prognosis in patients with chronic myeloid leukemia (CML) who are treated with hydroxyurea or interferon, its significance in patients on imatinib mesylate (IM) therapy is debated. METHODS: In the current study, the authors used a locus-specific indicator breakpoint cluster region/receptor tyrosine kinase (BCR/ABL) probe to evaluate the significance of del-der 9 in 163 patients with CML who had fluorescence in situ hybridization (FISH) results available. Serial changes in BCR/ABL fusion transcript levels also were monitored by using messenger RNA (mRNA) quantitative polymerase chain reaction (PCR). RESULTS: Of 163 patients, 22 (13.5%) had del-der 9 before commencing IM therapy. No differences were noted in the time to hematologic response (P = .598), major cytogenetic response (CyR) (P = .281), complete CyR (P = .883), major molecular response (MoR) (P = .125), or complete MoR (P = .834). In addition, the times to loss of response (LOR) (P = .974), treatment failure (P = .455; including primary hematologic or cytogenetic resistance and LOR), transformation-free survival (P = .276), and dose escalation of IM (P = .816) did not differ significantly between patients with and without del-der 9. The results of serial BCR/ABL mRNA quantitative PCR revealed similar patterns of BCR/ABL fusion gene reduction between the 2 groups. CONCLUSIONS: The presence of del-der 9 in patients with CML did not influence 1) the response to IM therapy in terms of hematologic response, CyR, or MoR; 2) LOR; 3) treatment failure; 4) progression to accelerated phase/blast crisis; or 5) time to dose escalation of IM. Therefore, the authors concluded that the detection of del-der 9 does not have an impact on the current management of patients with CML who are receiving IM therapy. CI - 2008 American Cancer Society FAU - Kim, Dong Hwan Dennis AU - Kim DH AD - Chronic Myelogenous Leukemia Group, Department of Hematology/Medical Oncology, Princess Margaret Hospital, University Health Network, University of Toronto, Toronto, Ontario, Canada. drkiim@medmail.co.kr FAU - Popradi, Gizelle AU - Popradi G FAU - Sriharsha, Lakshmi AU - Sriharsha L FAU - Kamel-Reid, Suzanne AU - Kamel-Reid S FAU - Chang, Hong AU - Chang H FAU - Messner, Hans A AU - Messner HA FAU - Lipton, Jeffrey H AU - Lipton JH LA - eng PT - Journal Article PL - United States TA - Cancer JT - Cancer JID - 0374236 RN - 0 (Benzamides) RN - 0 (Piperazines) RN - 0 (Pyrimidines) RN - 0 (RNA, Messenger) RN - 8A1O1M485B (Imatinib Mesylate) RN - EC 2.7.10.2 (Fusion Proteins, bcr-abl) SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Benzamides MH - *Chromosome Deletion MH - *Chromosomes, Human, Pair 9 MH - Female MH - Fusion Proteins, bcr-abl/*metabolism MH - Humans MH - Imatinib Mesylate MH - Leukemia, Myelogenous, Chronic, BCR-ABL Positive/*genetics MH - Male MH - Middle Aged MH - Piperazines/administration & dosage/*therapeutic use MH - Pyrimidines/administration & dosage/*therapeutic use MH - RNA, Messenger/analysis MH - Retrospective Studies MH - Treatment Failure MH - Treatment Outcome EDAT- 2008/06/11 09:00 MHDA- 2008/09/09 09:00 CRDT- 2008/06/11 09:00 PHST- 2008/06/11 09:00 [pubmed] PHST- 2008/09/09 09:00 [medline] PHST- 2008/06/11 09:00 [entrez] AID - 10.1002/cncr.23607 [doi] PST - ppublish SO - Cancer. 2008 Aug 15;113(4):772-81. doi: 10.1002/cncr.23607.